Literature DB >> 32199943

Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2.

Ye Qiu1, Yuan-Bo Zhao1, Qiong Wang1, Jin-Yan Li1, Zhi-Jian Zhou1, Ce-Heng Liao1, Xing-Yi Ge2.   

Abstract

SARS-CoV-2, the newly identified human coronavirus causing severe pneumonia pandemic, was probably originated from Chinese horseshoe bats. However, direct transmission of the virus from bats to humans is unlikely due to lack of direct contact, implying the existence of unknown intermediate hosts. Angiotensin converting enzyme 2 (ACE2) is the receptor of SARS-CoV-2, but only ACE2s of certain species can be utilized by SARS-CoV-2. Here, we evaluated and ranked the receptor-utilizing capability of ACE2s from various species by phylogenetic clustering and sequence alignment with the currently known ACE2s utilized by SARS-CoV-2. As a result, we predicted that SARS-CoV-2 tends to utilize ACE2s of various mammals, except murines, and some birds, such as pigeon. This prediction may help to screen the intermediate hosts of SARS-CoV-2.
Copyright © 2020 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Angiotensin converting enzyme 2 (ACE2); Coronavirus; Phylogenetic analysis; Receptor utilization; SARS-CoV-2

Mesh:

Substances:

Year:  2020        PMID: 32199943      PMCID: PMC7156207          DOI: 10.1016/j.micinf.2020.03.003

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


In December 2019, a novel human coronavirus, SARS-CoV-2, was detected in the city of Wuhan, China, and then the virus caused a severe pandemic of Coronavirus Disease 2019 (COVID-19) in China and worldwide, critically threatening the public health [1,2]. The pandemic has caused 80,813 confirmed infections with 3073 fatal cases in China by March 7th, 2020, surpassing any former coronavirus epidemics. Even worse, this virus emerges a worldwide spread currently and COVID-19 cases increased more rapidly than China in many countries around the world, including South Korean, Iran, Japan, Italy, Germany, France and United States. The interquartile deviation of the infection incubation period of SARS-CoV-2 is 2–7 days, but the maximum can be as long as 24 days according to the current reports, which is longer than other human coronaviruses and exacerbates the epidemic. The typical clinical symptoms of COVID-19 include fever, dry cough, dyspnea, headache, and pneumonia. Finally, COVID-19 may result in progressive respiratory failure due to alveolar damage and even death [[3], [4], [5]]. SARS-CoV-2 is an enveloped non-segmented positive sense RNA viruses classified into the Sarbecovirus subgenus of the genus Betacoronavirus in the subfamily Orthocoronavirinae, together with other severe acute respiratory syndrome-related coronaviruses (SARSr-CoVs), such as SARS-CoV [6]. Occasional interspecies transmission of virus is believed to be a major cause of coronavirus epidemic. SARS-CoV-2 has a high genetic relationship with a bat coronavirus (BatCoV RaTG13) with a 96% genomic nucleotide sequence identity. The close phylogenetic relationship to Bat RaTG13 provides evidence for a bat origin of SARS-CoV-2 [6]. However, direct transmission of the virus from bats to humans is unlikely due to the lack of direct contact between bats and humans. Hence, there are probably intermediate hosts transmitting SARS-CoV-2 to humans. This speculation is supported by the reports about the intermediate hosts of other human coronaviruses. For instance, SARS-CoV, the coronavirus causing SARS epidemic in 2003, was also originated from bats [7,8], but it transmitted to human via a variety of intermediate hosts including masked palm civet cats and raccoon dogs [9,10]. Since native reservoir hosts of viruses usually live far away from human community, intermediate hosts play critical roles in transmitting viruses to human and causing epidemics. A common way to determine the intermediate hosts is to collect all animals in the original epidemic area and detect the virus in them one by one, which is quite time- and labour-consuming and also is easy to be biased by passive contamination of the samples. Receptor recognition is an important factor determining host range and cross-species infection of viruses. Angiotensin converting enzyme 2 (ACE2) has been proved to be the cellular receptor of SARS-CoV-2 [6]. ACE2 was initially identified as an exopeptidase expressed in vascular endothelial cells in the heart and the kidney that catalyses the conversion of angiotensins [11,12]. Later, ACE2 was well known for its function as the virus receptor of SARS-CoV [13]. Utilization of ACE2 as the receptor by SARS-CoV-2 is an important rationale to classify SARS-CoV-2 to the same subgenus as SARS-CoV. ACE2 is expressed in most vertebrates, but not all ACEs can be utilized by SARS-CoV-2 as the receptor. Currently studies demonstrated that SARS-CoV-2 is able to use Chinese horseshoe bats, civet, swine but not mouse ACE2 as its entry receptor [6]. Obviously, the utilizing capability of ACE2 by SARS-CoV-2 can be used for quick screening to narrow down the range of the intermediate hosts for SARS-CoV-2. We intended to predict the utilizing capability by SARS-CoV-2 of different ACE2s via amino acid (aa) sequence comparison. Unfortunately, the aa identities between human ACE2 and ACE2s of Chinese horseshoe bats, civet, swine and mouse, are 80.75%, 83.48%, 81.37%, 82.11%, respectively. Mouse ACE2 which cannot be used by SARS-CoV-2 show higher similarity to human ACE2 than those of Chinese horseshoe bats and swine which can be used by SARS-CoV-2, indicating that whole aa sequence identities is not a good marker for predicting utilizing capability by SARS-CoV-2. In this study, we combined the phylogenetic analysis and critical site comparison of ACE2 to predict the intermediate hosts of SARS-CoV-2. First, we collected the aa sequences of ACE2s of 253 species and built a phylogenetic tree to cluster the ACE2s based on their evolutionary distance. In the tree, the ACE2s of species close to Chinese horseshoe bats, civet or swine but far from mouse were more likely to be utilized by SARS-CoV-2. Second, we aligned the aa sequences of ACE2s of Chinese horseshoe bats, civet, swine and mouse to identify the sites critical for SARS-CoV-2 utilization; then we ranked the ACE2s of other species according to their aa substitution on these sites. The top hits were selected to be the candidates potentially utilized by SARS-CoV-2. Combining the results obtained by the two methods and considering the living animals, we predicted pangolin, cat, cow, buffalo, goat, sheep and pigeon as the potential intermediate hosts for SARS-CoV-2, together with civet or swine. These results may help the screening for the intermediate hosts of SARS-CoV-2, contributing to the study of the viral transmission and disease control.

Methods and materials

Phylogenetic analysis

The aa sequences of ACE2s of Homo sapiens (human), Rhinolophus sinicus (Chinese horseshoe bat), Paguma Larvata (civet), Sus scrofa (swine) and Mus musculus (mouse) were downloaded from UniProt Knowledgebase; the rest of 248 vertebrate species were downloaded from GenBank (File S1). Multiple sequence alignment was performed for the whole aa sequences of ACEs using MAFFT with a local alignment strategy FFT-NS-2. The phylogenetic tree was constructed by MEGA7 using the neighbour-joining (NJ) method with 1000 bootstrap replicates and visualized using FigTree.

Marking of utilizing capability by SARS-CoV-2

The critical aa sites for the utilization by SARS-CoV-2 were selected by picking the unique aa residues in mouse ACE2 which distinct from human ACE2 and the sites reported to be critical for the receptor binding of SARS-CoV in the previous study [14]. The initial mark for every ACE2 was 100 and the substitution on each critical sites resulted in a reduction of its mark of 50 (for substitutions reported to abolish the receptor binding of SARS-CoV) or 10 (for other substitutions). The utilizing capability by SARS-CoV-2 of the ACE2s were ranked by the final scores and ACE2s with scores >50 were considered to be potentially utilized by SARS-CoV-2.

Results and discussion

To evaluate the homology of ACE2s in different species, we built a phylogenetic tree haboring ACE2s of 253 vertebrate species (Fig. S1). The tree was branched to two major groups. The first group included the classes of Mammalia, Aves and Reprilia, and the second group included the classes of Amphibian, Chondrichthyes and Teleostomi. This tree indicated that besides mammalia, ACE2s of aves and reprilia were more likely to be utilized by SARS-CoV-2 than other vertebrates. As shown in Fig. 1 , among mammals, human ACE2 was clustered with bat, civet and swine ACE2s but not mouse ACE2, matching the previous report about the utilizing capability by SARS-CoV-2 of these ACE2s. Intriguingly, cat, pangolin, cow and goat ACE2s were also clustered with human ACE2. Considering the widespread of stray cats, wildlife markets and stock farms, it was not strange that these animals could serve as potential intermediate hosts of SARS-CoV-2. Indeed, it was reported in the local news that SARS-CoV-2 was detected in pangolins, though further verification is required.
Fig. 1

Part of the phylogenetic tree of ACE2s from selected species. The tree was constructed on the whole aa sequences of ACE2s using NJ method by MEGA7 with 1000 bootstrap replicates. The utilizing capability of every ACE2 was marked with different labelled as indicated. The ACE2 sequence of Homo sapiens (Q9BYF1), Rhinolophus sinicus (U5WHY8), Paguma Larvata (Q56NL1), Sus scrofa (K7GLM4) and Mus musculus (Q8R0I0) were downloaded from UniProt Knowledgebase. The rest were downloaded from GenBank as follows: Capra hircus (AHI85757.1), Ovis aries (XP_011961657.1), Bos taurus (XP_005228485.1), Bubalus bubalis (XP_006041602.1), Equus caballus (XP_001490241.1), Pteropus alecto (XP_006911709.1), Manis javanica (XP_017505752.1), Mustela ermine (XP_032187679.1), Canis lupus dingo (XP_025292934.1), Felis catus (AAX59005.1), Lynx Canadensis (XP_030160839.1), Dasypus novemcinctus (XP_004449124.1), Rattus norvegicus (NP_001012006.1), Grammomys surdaster (XP_028617962.1), Mus caroli (XP_021009138.1), Nestor notabilis (XP_021009138.1), Merops nubicus (XP_010012481.1), Egretta garzetta (XP_009638257.1), Apaloderma vittatum (XP_009867056.1), Colius striatus (XP_009082150.1), Columba livia (PKK30539.1), Rotobothrops mucrosquamatus (XP_029140508.1).

Part of the phylogenetic tree of ACE2s from selected species. The tree was constructed on the whole aa sequences of ACE2s using NJ method by MEGA7 with 1000 bootstrap replicates. The utilizing capability of every ACE2 was marked with different labelled as indicated. The ACE2 sequence of Homo sapiens (Q9BYF1), Rhinolophus sinicus (U5WHY8), Paguma Larvata (Q56NL1), Sus scrofa (K7GLM4) and Mus musculus (Q8R0I0) were downloaded from UniProt Knowledgebase. The rest were downloaded from GenBank as follows: Capra hircus (AHI85757.1), Ovis aries (XP_011961657.1), Bos taurus (XP_005228485.1), Bubalus bubalis (XP_006041602.1), Equus caballus (XP_001490241.1), Pteropus alecto (XP_006911709.1), Manis javanica (XP_017505752.1), Mustela ermine (XP_032187679.1), Canis lupus dingo (XP_025292934.1), Felis catus (AAX59005.1), Lynx Canadensis (XP_030160839.1), Dasypus novemcinctus (XP_004449124.1), Rattus norvegicus (NP_001012006.1), Grammomys surdaster (XP_028617962.1), Mus caroli (XP_021009138.1), Nestor notabilis (XP_021009138.1), Merops nubicus (XP_010012481.1), Egretta garzetta (XP_009638257.1), Apaloderma vittatum (XP_009867056.1), Colius striatus (XP_009082150.1), Columba livia (PKK30539.1), Rotobothrops mucrosquamatus (XP_029140508.1). We further tried to predict the receptor utilizing capability by SARS-CoV-2 via looking into the critical single aa polymorphism in different ACE2s. We screened the aa sites critical for SARS-CoV-2 utilization by two approaches. First, it has been proved that human, Chinese horseshoe bats, civet and swine ACE2s can be utilized by SARS-CoV-2 but mouse ACE2 cannot [6]. We aligned the aa sequence of these five ACE2s (File S2). Eleven aa residues distinct in mouse ACE2 but conserved in other ACE2s were identified, which were T20, Y83, S218, A246, K353, P426, T593, N636, A714, R716 and A774. However, according to the complex structure of human ACE2 and the receptor binding domain (RBD) in SARS-CoV-2 S protein (PDB ID: 6VW1), only three of the eleven sites are located near the interface and potentially mediate the binding, which were T20, Y83 and K353 (Fig. 2 A). Second, SARS-CoV-2 shares an identity of 74.6% with SARS-CoV in the aa sequences of their RBDs, and thus the aa residues critical for the receptor binding of SARS-CoV may be also critical for SARS-CoV-2. According to the previous study, such critical sites include K31, Y41, K68, Y83, K353, D355, R357 and M383 [14]. Among these sites, K31D, Y41A, Y83F, K353 H/A/D, D355A and R357A abolish or strongly inhibit SARS-CoV binding, while the substitutions on K68 and M383 slightly inhibit SARS-CoV binding [14,15]. Combining the two screening, we got nine critical aa sites as shown in Fig. 2B. Based on these sites, we established a marking system to evaluate the utilizing capability by SARS-CoV-2 of different ACE2s. In the system, the initial score for every ACE2 was 100 and substitution on the critical sites would result in reduction of 50 marks (for K31D, Y41A, Y83F, K353 H/A/D, D355A and R357A) or 10 marks (for other substitutions). K31T and Y41H would not reduce the scores since these two substitutions exist in civet and Chinese horseshoe bat ACE2s, respectively (Fig. 2B). A final score less than 0 was adjusted to 0. As the result, a final score equal to or less than 50 means that the ACE2 contains either at least one substitution that will abolish the receptor binding or at least five other substitutions that will make it quite different from human ACE2. Therefore, the ACE2s with final scores higher than 50 were considered to be potentially utilized by SARS-CoV-2, while those with scores less or equal to 50 were unlikely to be utilized by SARS-CoV-2. The final scores for all ACE2s we analysed were listed in Table S1. As shown in Table 1 , excluding the animals unlikely contacted by people, pangolin, cat, cow, buffalo, goat and sheep ACE2 were ranked as the top mammals that could be potentially used by SARS-CoV-2, while murine ACE2s, such as mouse and rat ACE2s, got the lowest scores. As for birds, pigeon ACE2 reached the highest score of 70 (Table 1). Though birds are not natural reserviors for currently know species of betacoronavirus, the classification of coronaviruses is based on the genome feature not the host range, and thus we could not exclude the possibility that new betacoronavirus may infect birds. Considering pigeons are food in many places around the world, more attention should be paid on the non-mammalian hosts of SARS-CoV-2. ACE2 of Protobothrops mucrosquamatus (pallas pit viper), a common snake, got a score of 20, indicating that reprilia ACE2s were unlikely to be utilized by SARS-CoV-2. To verify the robustness of our ranking system, we labelled the utilizing capability of different ACE2s on the phylogenetic tree, and found that the ACE2s confirmed or potential to be utilized by SARS-CoV-2 (labelled with circles) were obviously clustered from those unlikely to be utilized by SARS-CoV-2 (labelled with triangles) (Fig. 1). The well matching with the phylogenetic tree elevated the liability of this marking system.
Fig. 2

Critical amino acid sites predicted for the utilization of SARS-CoV-2. (A) The structure of the binding complex of human ACE2 and SARS-CoV-2 RBD. The structure was adapted from Protein Data Bank (PDB ID: 6VW1) and the aa residues distinct in mouse ACE2 (T20, Y83, S218, A246, K353, P426 and T593) are labelled with red. N636, A714, R716 and A774 are not included in the structure, since they are too far away from the interface and were not crystallized in the structure analysis. (B) The aa sequences of Homo sapiens (Human), Rhinolophus sinicus (Bat), Paguma Larvata (Civet), Sus scrofa (swine) and Mus musculus (mouse) ACE2s were aligned. The critical sites identified by the alignment were highlighted with yellow background. The critical sites reported in SARS-CoV binding are highlighted with red font.

Table 1

Marks for ACE2s of selected animals.

Critical amino acid sites predicted for the utilization of SARS-CoV-2. (A) The structure of the binding complex of human ACE2 and SARS-CoV-2 RBD. The structure was adapted from Protein Data Bank (PDB ID: 6VW1) and the aa residues distinct in mouse ACE2 (T20, Y83, S218, A246, K353, P426 and T593) are labelled with red. N636, A714, R716 and A774 are not included in the structure, since they are too far away from the interface and were not crystallized in the structure analysis. (B) The aa sequences of Homo sapiens (Human), Rhinolophus sinicus (Bat), Paguma Larvata (Civet), Sus scrofa (swine) and Mus musculus (mouse) ACE2s were aligned. The critical sites identified by the alignment were highlighted with yellow background. The critical sites reported in SARS-CoV binding are highlighted with red font. Marks for ACE2s of selected animals. In summary, we combined phylogenetic analysis and critical site marking to predict the utilizing capability of ACE2s from different animal species by SARS-CoV-2. The results from these two analysis matched each other quite well, indicating relative reliability of our prediction. We have shown that, besides currently confirmed ACE2s utilized by SARS-CoV-2, pangolin, cat, cow, buffalo, goat, sheep and pigeon ACE2s might be utilized by SARS-CoV-2, indicating potential interspecies transmission of the virus from bats to these animals and among these animals. Considering the widespread existing of these animals, some of them might serve as intermediate hosts for SARS-CoV-2, which called for the attention in disease control. However, these are still preliminary results predicted by sequence analysis which cannot accurately reflect the infection in the animals, and more laboratory and epidemiological investigation are required to uncover the true intermediate hosts of SARS-CoV-2.

Declaration of Competing Interest

The authors declare no competing interests.
  15 in total

1.  A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9.

Authors:  M Donoghue; F Hsieh; E Baronas; K Godbout; M Gosselin; N Stagliano; M Donovan; B Woolf; K Robison; R Jeyaseelan; R E Breitbart; S Acton
Journal:  Circ Res       Date:  2000-09-01       Impact factor: 17.367

Review 2.  SARS-CoV and emergent coronaviruses: viral determinants of interspecies transmission.

Authors:  Meagan Bolles; Eric Donaldson; Ralph Baric
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

3.  Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2.

Authors:  Wenhui Li; Chengsheng Zhang; Jianhua Sui; Jens H Kuhn; Michael J Moore; Shiwen Luo; Swee-Kee Wong; I-Chueh Huang; Keming Xu; Natalya Vasilieva; Akikazu Murakami; Yaqing He; Wayne A Marasco; Yi Guan; Hyeryun Choe; Michael Farzan
Journal:  EMBO J       Date:  2005-03-24       Impact factor: 11.598

4.  Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.

Authors:  Xing-Yi Ge; Jia-Lu Li; Xing-Lou Yang; Aleksei A Chmura; Guangjian Zhu; Jonathan H Epstein; Jonna K Mazet; Ben Hu; Wei Zhang; Cheng Peng; Yu-Ji Zhang; Chu-Ming Luo; Bing Tan; Ning Wang; Yan Zhu; Gary Crameri; Shu-Yi Zhang; Lin-Fa Wang; Peter Daszak; Zheng-Li Shi
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

Review 6.  Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function.

Authors:  Carlos M Ferrario; Aaron J Trask; Jewell A Jessup
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-29       Impact factor: 4.733

7.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.

Authors:  Keiji Kuba; Yumiko Imai; Shuan Rao; Hong Gao; Feng Guo; Bin Guan; Yi Huan; Peng Yang; Yanli Zhang; Wei Deng; Linlin Bao; Binlin Zhang; Guang Liu; Zhong Wang; Mark Chappell; Yanxin Liu; Dexian Zheng; Andreas Leibbrandt; Teiji Wada; Arthur S Slutsky; Depei Liu; Chuan Qin; Chengyu Jiang; Josef M Penninger
Journal:  Nat Med       Date:  2005-07-10       Impact factor: 53.440

8.  Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus.

Authors:  Yushun Wan; Jian Shang; Rachel Graham; Ralph S Baric; Fang Li
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

9.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

Review 10.  A review of studies on animal reservoirs of the SARS coronavirus.

Authors:  Zhengli Shi; Zhihong Hu
Journal:  Virus Res       Date:  2007-04-23       Impact factor: 3.303

View more
  81 in total

1.  Risks of Zoonotic Transmission of COVID-19 During Eid-Ul-Adha in Pakistan.

Authors:  Tauqeer Hussain Mallhi; Yusra Habib Khan; Muhammad Hammad Butt; Aroosa Liaqat; Arooj Abid; Abrar Ahmad; Shahzadi Misbah
Journal:  Disaster Med Public Health Prep       Date:  2020-07-27       Impact factor: 1.385

Review 2.  The mouse resource at National Resource Center for Mutant Mice.

Authors:  Cunxiang Ju; Juan Liang; Mingkun Zhang; Jinlong Zhao; Ling'en Li; Shuai Chen; Jing Zhao; Xiang Gao
Journal:  Mamm Genome       Date:  2022-02-09       Impact factor: 2.957

3.  Noninvasive Mapping of Angiotensin Converting Enzyme-2 in Pigeons Using Micro Positron Emission Tomography.

Authors:  Zilei Wang; Ziyu Liu; Lanxin Yang; Jin Ding; Feng Wang; Teli Liu; Zhi Yang; Chao Wang; Hua Zhu; Youping Liu
Journal:  Life (Basel)       Date:  2022-05-26

Review 4.  Role of natural products towards the SARS-CoV-2: A critical review.

Authors:  Kannan Raman; Kalirajan Rajagopal; Fahadul Islam; Manish Dhawan; Saikat Mitra; Baliwada Aparna; Potlapati Varakumar; Gowramma Byran; Om Prakash Choudhary; Talha Bin Emran
Journal:  Ann Med Surg (Lond)       Date:  2022-07-02

Review 5.  In the eye of the storm: SARS-CoV-2 infection and replication at the ocular surface?

Authors:  Lyle Armstrong; Joseph Collin; Islam Mostafa; Rachel Queen; Francisco C Figueiredo; Majlinda Lako
Journal:  Stem Cells Transl Med       Date:  2021-03-12       Impact factor: 6.940

Review 6.  SARS-CoV-2 viability under different meteorological conditions, surfaces, fluids and transmission between animals.

Authors:  María Fernández-Raga; Laura Díaz-Marugán; Marta García Escolano; Carlos Bort; Víctor Fanjul
Journal:  Environ Res       Date:  2020-10-02       Impact factor: 6.498

Review 7.  Should We Be Concerned about the Association of Diabetes Mellitus and Periodontal Disease in the Risk of Infection by SARS-CoV-2? A Systematic Review and Hypothesis.

Authors:  Miguel Angel Casillas Santana; Juan Antonio Arreguín Cano; Alejandro Dib Kanán; Farid Alonso Dipp Velázquez; Paulina Del Carmen Sosa Munguía; Gabriel Alejandro Martínez Castañón; Brenda Eréndida Castillo Silva; Carolina Sámano Valencia; Marco Felipe Salas Orozco
Journal:  Medicina (Kaunas)       Date:  2021-05-13       Impact factor: 2.430

8.  In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin.

Authors:  Sakshi Piplani; Puneet Kumar Singh; David A Winkler; Nikolai Petrovsky
Journal:  Sci Rep       Date:  2021-06-24       Impact factor: 4.379

9.  Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients.

Authors:  Ikram Omar Osman; Cléa Melenotte; Philippe Brouqui; Matthieu Million; Jean-Christophe Lagier; Philippe Parola; Andréas Stein; Bernard La Scola; Line Meddeb; Jean-Louis Mege; Didier Raoult; Christian A Devaux
Journal:  Front Immunol       Date:  2021-06-14       Impact factor: 7.561

Review 10.  Monitoring of new coronavirus (SARS-CoV-2): Origin, transmission, and food preservation methods.

Authors:  Reza Farahmandfar; Maryam Asnaashari; Bakhtiyar Hesami
Journal:  J Food Process Preserv       Date:  2021-06-12       Impact factor: 2.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.